USNA vs. PBH, HLF, NUS, NATR, MED, VERU, EL, IPAR, TLRY, and CRON
Should you be buying USANA Health Sciences stock or one of its competitors? The main competitors of USANA Health Sciences include Prestige Consumer Healthcare (PBH), Herbalife (HLF), Nu Skin Enterprises (NUS), Nature's Sunshine Products (NATR), Medifast (MED), Veru (VERU), Estée Lauder Companies (EL), Inter Parfums (IPAR), Tilray (TLRY), and Cronos Group (CRON).
USANA Health Sciences (NYSE:USNA) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, community ranking, dividends, risk, earnings, media sentiment and valuation.
USANA Health Sciences has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.
Prestige Consumer Healthcare has a net margin of 18.60% compared to USANA Health Sciences' net margin of 6.88%. Prestige Consumer Healthcare's return on equity of 13.48% beat USANA Health Sciences' return on equity.
In the previous week, USANA Health Sciences had 5 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 9 mentions for USANA Health Sciences and 4 mentions for Prestige Consumer Healthcare. USANA Health Sciences' average media sentiment score of 0.75 beat Prestige Consumer Healthcare's score of 0.63 indicating that USANA Health Sciences is being referred to more favorably in the media.
54.3% of USANA Health Sciences shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 0.3% of USANA Health Sciences shares are held by company insiders. Comparatively, 1.6% of Prestige Consumer Healthcare shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Prestige Consumer Healthcare has higher revenue and earnings than USANA Health Sciences. USANA Health Sciences is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.
USANA Health Sciences presently has a consensus price target of $46.00, indicating a potential downside of 1.33%. Prestige Consumer Healthcare has a consensus price target of $91.25, indicating a potential upside of 43.45%. Given Prestige Consumer Healthcare's higher possible upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than USANA Health Sciences.
Prestige Consumer Healthcare received 90 more outperform votes than USANA Health Sciences when rated by MarketBeat users. Likewise, 70.70% of users gave Prestige Consumer Healthcare an outperform vote while only 60.68% of users gave USANA Health Sciences an outperform vote.
Summary
Prestige Consumer Healthcare beats USANA Health Sciences on 13 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding USNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
USANA Health Sciences Competitors List
Related Companies and Tools
